OS Therapies Inc (NYSE:OSTX - Get Free Report) major shareholder Shalom Auerbach sold 50,012 shares of OS Therapies stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.35, for a total transaction of $67,516.20. Following the completion of the transaction, the insider now directly owns 2,756,199 shares of the company's stock, valued at $3,720,868.65. This trade represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Shalom Auerbach also recently made the following trade(s):
- On Friday, February 14th, Shalom Auerbach sold 100,000 shares of OS Therapies stock. The stock was sold at an average price of $2.84, for a total transaction of $284,000.00.
- On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The shares were sold at an average price of $6.74, for a total value of $112,692.80.
OS Therapies Trading Up 11.6 %
Shares of NYSE OSTX opened at $1.25 on Friday. OS Therapies Inc has a 12-month low of $1.12 and a 12-month high of $7.00. The stock has a 50 day simple moving average of $1.65 and a 200-day simple moving average of $2.58.
Wall Street Analysts Forecast Growth
OSTX has been the topic of several recent research reports. Maxim Group raised their price target on OS Therapies from $8.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, January 16th. D. Boral Capital reiterated a "buy" rating and issued a $20.00 target price on shares of OS Therapies in a research note on Monday, April 7th. Finally, Lake Street Capital started coverage on shares of OS Therapies in a research report on Wednesday, April 2nd. They set a "buy" rating and a $19.00 price target for the company. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $18.00.
View Our Latest Stock Analysis on OSTX
Institutional Trading of OS Therapies
An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in shares of OS Therapies Inc (NYSE:OSTX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,045 shares of the company's stock, valued at approximately $28,000.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
